Information Provided By: 
Fly News Breaks for September 7, 2016
CNC
Sep 7, 2016 | 09:12 EDT
After Leerink downgraded Centene and the stock fell 5%, Wedbush analyst Sarah James says that the decline in the stock is overdone. James thinks that the company could benefit in the near-term from the resolution of California PPO price increases and benefit design changes. The analyst thinks that the company should continue to benefit from Medicaid growth, and she expects the stock to rebound in the wake of appearances by Centene's management at conferences this week. James keeps an $85 price target and Outperform rating on the shares.
News For CNC From the Last 2 Days
